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ABSTRACT 
Introduction.  Epithelial ovarian cancer is associated with high recurrence rates and poor survival, 
especially if the disease is advanced, surgery sub-optimal, and or has high-grade histology. However, 
there is a paucity of information regarding recurrence and survival in epithelial ovarian cancer in 
Africa. We aimed to assess early recurrence rate, associated factors, and patterns of recurrence of 
epithelial ovarian cancer, at a tertiary centre in South Africa. 
Materials and Methods. A retrospective review of records of patients with epithelial ovarian cancer 
managed in a single institution over a nine-year period was performed with relevant ethics approval 
(S18/04/078). Case records were searched and information about age, parity, baseline serum 
CA125, histologic sub-type and grade, FIGO stage, neoadjuvant and adjuvant chemotherapy status 
and number of cycles, optimality of staging/debulking surgery, the month adjuvant treatment was 
completed, and month of recurrence were abstracted. Exclusion criteria included documented 
primary peritoneal cancer, platinum-resistant patients, and those with inadequate follow-up 
information. IBM SPSS version 25® was used for statistical analysis. Descriptive statistics which 
included percentages, means and medians, were used to assess recurrence. Fisher’s exact and χ² 
tests were used to assess for factors with significant association to early recurrence. 
p-value<0.05 was considered statistically significant.
Results. A total of 124 patients definitively treated for epithelial ovarian cancer with adequate 
records were identified. Final analysis was performed for 91 patients after 33 were excluded. Early-
stage disease comprised 47% of the cases. Nearly 50% of patients had papillary serous histology. 
Optimal cytoreduction was achieved in 70% of cases. Recurrence rate ≤ 24 months was 33% with a 
median time to recurrence of 14 months (IQR 8.75-20.75) for stages I and II disease, and 67% with 
a median time to recurrence of 12 months (IQR 8-14.25) for stages III and IV disease. Isolated pelvic 
recurrence was diagnosed in 50% of early- stage disease but, a trend towards multiple distant-site 
recurrence was observed in FIGO stage III/IV disease. Tumour histology was the only significant 
factor associated with early recurrence (p=0.005). Cytoreduction status, use of neoadjuvant 
chemotherapy, baseline CA125, parity, and patient age did not demonstrate association with early 
recurrence. Conclusions. Early recurrence of epithelial ovarian cancer in this patient population 
appears higher compared to published literature. However, a standardized surgical protocol, 
objective intra-operative assessment of residual tumour, and adequate surgical record are essential 
for an in-depth study of surgical factors in ovarian cancer recurrence for our setting. 
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OPERATIONAL DEFINITIONS 
“Recurrence” was defined as documented new imaging abnormality, deterioration of clinical 
picture, and/or raised serum CA 125 twice the normal post-treatment value, and/or new positive 
histo/cyto-pathologic report at least six months after completion of adjuvant chemotherapy. 
“Early recurrence” was defined as occurrence of disease under two years of completion of adjuvant 
therapy. 
“Recurrence-Free Interval’’ (RFI) was defined as the duration in months, from completing adjuvant 
chemotherapy to first recurrence of disease. 
“Patterns of recurrence” implied disease distribution at recurrence 
“Definitive treatment” was considered as a combination of surgery (at least TAH+ BSO + 
omentectomy) followed by ≥ three cycles of adjuvant chemotherapy, or surgery alone for FIGO stage 
IA/B grade 1 disease. 
“Adequate surgical staging” was defined as cytologic evaluation of ascitic fluid, peritoneal biopsies, 
total abdominal hysterectomy with bilateral salpingo-oophorectomy, omentectomy, pelvic and 
para-aortic lymphadenectomy in patients with disease clinically confined to the pelvis.  
“Optimal debulking surgery” was defined as total abdominal hysterectomy with bilateral salpingo-
oophorectomy, omentectomy and tumour debulking to ≤ 1.0 cm of residual disease. 
“Ultra-radical surgery” included multiple bowel resections, splenectomy, and or 
peritoneal/diaphragmatic stripping. 
“Early-stage disease” was collectively considered as stages I and II disease, while high-risk early- 
stage disease comprised stages IA/B with grade 2-3 histology, IC, and IIA/B regardless of tumour 
grade. 
“Advanced-stage disease” included both FIGO stages III and IV. 
Type I epithelial ovarian cancer includes clear-cell, mucinous, endometrioid and low-grade serous 
histologies. 
Type II tumours include high-grade serous, mixed epithelial -stromal and undifferentiated 
carcinoma. 
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CHAPTER ONE: INTRODUCTION 
1.1 Background 
The five-year survival after diagnosis of EOC is generally around 30% in contrast to other gynecologic 
malignancies, and across the globe there is wide disparity in survival with majority of the developing 
world having much lower survival figures (1,2). 
The standard management of EOC is optimal staging/primary debulking surgery (PDS) followed by 
three to six cycles of timely adjuvant chemotherapy (ACT) (3–7). When disease is clinically confined 
to the pelvis, para-aortic and pelvic lymphadenectomy upstages one-third of patients, but its impact 
on prognosis is still debatable (8–10). 
Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) in patients with 
advanced disease and high-tumour load (HTL) is an acceptable alternative to PDS to minimize 
surgical morbidity without compromising survival (11–13).  
The objective of surgery regardless of approach is to resect all macroscopic tumour or at a minimum 
achieve residual tumour ≤ 1cm as residual disease volume inversely correlates with survival (14). 
While optimal surgical effort is the cornerstone of EOC treatment, other patient and tumour-related 
factors potentially influence surgical and survival outcomes. 
The impact of adjuvant chemotherapy regime on recurrence and survival was established two 
decades ago. Combination of platinum and paclitaxel results in superior recurrence-free and overall 
survival compared to platinum and cyclophosphamide particularly when debulking surgery is sub-
optimal (15). 
At Tygerberg Hospital, pelvic and paraaortic lymphadenectomy, a component of standard staging 
surgery is not routine. Rather, patients with high-risk stage I and stage II EOC receive three to six 
cycles of single-agent carboplatin or carboplatin in combination with paclitaxel or 
cyclophosphamide: the latter being the most commonly used combination until recently. To 
minimize the need for ultra-radical surgery, patients with advanced-stage disease with clinical and 
radiologic HTL undergo IDS three weeks after last NACT cycle. The justification for these approaches 
is limited theatre time and ICU support services. Anecdotal information however, suggests that 
optimal surgery rate for EOC at our institution may be modest regardless of approach.   
Stellenbosch University  https://scholar.sun.ac.za
11 | Page 
 
 1.2 Problem statement  
Recurrence after treatment of EOC at Tygerberg hospital is not well documented. 
 1.3 Justification 
Early recurrence in ovarian cancer is in part a reflection of the adequacy of surgery performed. This 
study would determine the need for generation of a surgical protocol to obtain maximum surgical 
benefit in a modestly resourced setting. It would also provide information to future investigators 
interested in epithelial ovarian cancer survival for the South African population. 
1.4 Outcomes of the study 
1.4.1 Primary outcome 
The recurrence rate at 24 months among patients managed for EOC. 
1.4.2 Secondary outcomes 
1. Contributing factors to early recurrence  
2. Patterns of disease recurrence 
 
 
 
  
Stellenbosch University  https://scholar.sun.ac.za
12 | Page 
 
CHAPTER TWO: LITERATURE REVIEW 
2.1 Epidemiology of epithelial ovarian cancer 
Epithelial ovarian cancer (EOC) constitutes more than two-thirds of the ovarian cancer (OC) burden 
with a mean age at diagnosis of 58 and 64 years for types I and II tumours respectively (2). High-
grade serous (HGS) carcinoma is the most prevalent and often presents with advanced-stage disease 
(16,17). 
The five-year survival for FIGO stages IA, IB, IC, II, IIIA, IIIB, IIIC and IV EOC is 89.6%, 86.1%, 83.4%, 
70.7%, 46.7%, 41.5%, 32.5% , and 18.6% respectively (18). Generally, survival for all stages of OC has 
modestly improved from 29% in the 1970s to 39% in 2006, in part due to improvements in surgical 
care and chemotherapy (1,18). However, there still remains wide disparity in survival with inferior 
outcomes observed in the developing world. (1,2,19). Survival data for ovarian cancer in Sub-
Saharan Africa is disappointingly very scanty. 
2.2 Disease recurrence and prognostic factors 
Recurrence after primary treatment for high-risk early and advanced EOC is often the rule. The 
median recurrence-free interval (RFI) for high-risk early-stage disease is 21 months, and although 
early-stage disease has a good prognosis, the median overall survival after recurrence is poor and 
comparable to recurrent advanced-stage disease (20). 
Data from multiple cohorts indicate that residual tumour size after debulking surgery is a critical 
factor in determining recurrence-free survival (RFS) in advanced-stage disease (21). Patients who 
are optimally treated achieve 38 months of RFS compared to 10 months for those with sub-optimal 
residual disease (14). Furthermore, there is a 5.5% increment in median overall survival for every 
10% of that cohort who attain complete debulking (22). 
The FIGO stage and tumour burden are influenced by patient age, histologic sub-type and tumour 
grade. Age over 60 years, HGS carcinoma and other poorly-differentiated epithelial sub-types are 
associated with advanced disease and high-tumour burden (23,24). HTL is an independent poor 
prognostic factor and probably a reflection of an inherent aggressive tumour behavior (25).  
HGS carcinoma demonstrates a higher response to platinum-based chemotherapy than clear-cell 
and mucinous variants (5). In addition to affecting platinum sensitivity, tumour grade influences 
recurrence patterns with high-grade disease often recurring in distant sites irrespective of FIGO 
stage of disease (26). 
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A correlation between tumour biology and CA125 levels has been observed. High serum CA125 level 
is associated with wide spread metastatic disease, a common occurrence with poorly differentiated 
tumours (27). But, the surgical utility of serum CA125 level is not well established, and various 
cutoffs that have been set to predict optimal PDS have low positive predictive value (PPV) (28,29). 
Conversely, post-NACT serum CA125 level appears to accurately predict complete IDS but this has 
not been validated (30,31). 
The impact of gene mutations in EOC is an emerging field. It is estimated that about 15% of women 
with non-mucinous, but predominantly HGS have a BRCA gene mutation (32). BRCA mutations have 
been reported by some authors to confer superior survival compared to sporadic variants, partly 
due to increased platinum sensitivity and utility of PARP inhibitors (33). A recent study indicates that 
nearly one-fourth of all EOC patients carry a homologous recombination deficiency (HRD) gene with 
observed superior survival in contrast to non-HRD patients (34).  However, high levels of PARP, 
FANCD2 and or P53, are associated with a cumulative first year cancer incidence of 17% and high 
platinum resistance, in contrast with tumours that express PTEN, H2AX and ATM (35). Limited 
published data indicate that BRCA mutations are uncommon in the South African black population 
(36). But the level of non-BRCA HRD in this population is also not established. 
Attempts have been made to stratify patients into low, intermediate, and high risk of recurrence 
based on FIGO stage, histologic sub-type and grade, baseline and post-adjuvant chemotherapy 
serum CA125 level, residual disease status after debulking surgery, and post-adjuvant 
chemotherapy (37). Validation of such a prognostic score would help to tailor follow-up and utilize 
resources rationally. 
2.3 Primary management of Epithelial Ovarian Cancer 
The standard treatment of EOC is upfront staging/debulking surgery to achieve largest residual 
tumour of less than 1 cm, followed by timely adjuvant platinum and taxane-based chemotherapy 
(6,15). Optimally-staged IA and IB grade 1 disease does not require adjuvant chemotherapy (3).  
Patients with disease confined to the pelvis undergo a full staging operation inclusive of para-aortic 
(up to renal vessels) and pelvic lymph node dissection (6,38). This is due to the fact that 37% of 
patients with apparent early-stage EOC will be up-staged on the basis of occult retroperitoneal 
lymph node metastases (8), and this has an impact on adjuvant chemotherapy and prognosis. Some 
schools of thought have questioned the need for extensive lymphadenectomy as this has no bearing 
on survival, and high-risk stage I and II disease is, nonetheless treated with adjuvant chemotherapy 
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(10,39). The setback of this strategy is that nearly one-third of patients who are considered to have 
early-stage disease actually have stage III disease (40), and their survival is inferior to actual stage I 
and II patients.  
In advanced EOC, optimal debulking surgery offers improved survival outcomes (6,41). Due to the 
disease’s propensity for parietal and visceral peritoneal spread to the abdominal cavity, radical, and 
or ultra-radical surgery is commonly required to achieve optimal/maximal cytoreduction with 
attendant severe morbidity and mortality of 5% (42–45). This has led to exploration of the role of 
NACT in patients with HTL. Randomized trials have shown that NACT followed by IDS in this category 
of patients offers better intra-operative and immediate post-operative outcomes compared to PDS 
(7,12,46). The proportion of optimal residual disease rate after NACT has been shown to be higher 
than after PDS, but the median overall survival was comparatively lower (11,41,46). Multi-visceral 
resection in IDS to achieve optimal/maximal cytoreduction does not translate into improved survival 
(25). Reduced impact of NACT on median overall survival may be related to inherent aggressive 
tumour biology and under-estimation of residual disease after IDS (25,47). Nevertheless, the 
benefits related to reduced intra-operative and immediate post-operative morbidity have made IDS 
an increasingly common approach for patients with HTL EOC in some European centres and the 
developing world (6,7,38). The value of IDS approach in HTL advanced EOC has brought forth triage 
laparoscopy to reduce futile PDS, a practice that has gained acceptance in some centres (6,48). 
It has been observed that optimality of surgery is influenced by level of training of the surgeon. 
Staging surgery performed by general gynecologists is commonly sub-optimal and associated with 
inferior survival in contrast to trained gynecologic oncologists (49,50). Optimal debulking rates 
correlate with patient volume as demonstrated by 70-90% optimal cytoreduction rates in some 
specialized high-volume centers in the developed world (51).  
2.4 management of epithelial ovarian cancer: A South African perspective 
The public oncology services, especially in the Western Cape Province, are centralized to tertiary 
centres. However, sub-optimal surgery for ovarian cancer by general gynecologists is not unusual. 
Triage laparoscopy in advanced-stage disease is not yet common practice in most tertiary 
institutions, but NACT followed by IDS is a common approach for advanced-stage disease in the 
public setting. 
A 2014 survey indicated that most gynecologic oncologists in South Africa achieved optimal 
cytoreduction in over 60% of cases of ovarian cancer. Nonetheless, more than 50% of them reported 
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a lack of expertise in upper abdominal procedures (52). A paucity of published data on ovarian 
cancer management and outcomes in South Africa hinders substantiation of these observations. 
2.5 Management of recurrent ovarian cancer 
It is well established that repeat use of carboplatin and paclitaxel for platinum-sensitive disease 
yields a superior median survival of 33 months with acceptable toxicity compared to other 
combinations (53). Additionally, the benefit of targeted agents in combination with chemotherapy 
and as maintenance therapy in platinum-sensitive disease is established (54–57). 
However, the utility of surgery in the management of recurrent disease is still uncertain. A role for 
secondary CRS in select patients has been observed and institutions use various validated criteria: 
AGO OVAR, Tian, and Memorial Sloan Kettering Cancer Centre criteria. Notably, RFI is the common 
denominator to determine probability of achieving no gross residual status in secondary CRS (58–
60). 
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CHAPTER THREE: METHODOLOGY 
3.1 Study design 
This was a retrospective review of patient records. 
3.2 Patient population and setting 
Patients definitively treated for EOC during the years 2006 to 2014 at the Gynecologic Oncology 
Unit, Department of Obstetrics and Gynecology, Tygerberg Hospital (TBH). TBH is one of two tertiary 
hospitals in the Western Cape Province of South Africa. 
3.3 Inclusion criteria 
Included all patients with documented EOC or Fallopian-tube cancer who underwent went definitive 
treatment. 
3.4 Exclusion criteria  
Borderline tumours, primary peritoneal cancer, uncertain histologic diagnosis, recurrence or 
progression under six months of completing ACT, fertility-sparing treatment, those who had less 
than three cycles of ACT, or had insufficient clinical information were excluded. 
3.5 Ethics Approval 
Ethics approval (S18/04/078) was obtained from the Health and Research Ethics Committee (HREC) 
of Stellenbosch University prior to commencement of the study.  
3.6 Data Collection 
All files of patients with an ovarian cancer diagnosis managed between January 2006 and December 
2014 were retrieved from the database of the gynecologic oncology unit. Those with a pathologic 
diagnosis of EOC/fallopian tube cancer were selected. The electronic database was searched to add 
relevant missing information. The treatment administered was then evaluated to identify those who 
met the inclusion criteria.  
Data collection consisted of patient age at diagnosis, parity, baseline serum CA125 level, FIGO stage, 
histologic sub-type and grade, NACT and number of treatment cycles, date of operation and residual 
tumour status, ACT and number of treatment cycles, date of completion of ACT, recurrence status, 
and date when diagnosis of recurrence was made, were abstracted.  
The surgical notes and pathology data were assessed to determine whether CRS and/or surgical 
staging was optimal. The sites of recurrence were recorded as per case notes. All FIGO stage IC 
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pathology reports were harmonized to reflect the FIGO 2014 staging format.  Recurrence-free 
interval (RFI) was estimated for each patient based on the month the patient completed ACT or had 
surgery alone-where ACT was not indicated, and the time of documented recurrence. Race was 
difficult to capture so it was ignored.  
Each patient file was given a unique ID consisting of a serial number and the year of treatment.  The 
database was password-protected and accessible only to the principal investigator on a personal 
computer to ensure confidentiality. 
3.7 Data Analysis 
The data were converted to Microsoft excel 2010 format and cleaned for completeness before 
exportation to IBM SPSS version 25® for analysis. Descriptive statistics were used to analyze the 
data. The following variables were evaluated: patient age, parity, baseline CA125, FIGO stage, 
histologic sub-type and grade, NACT, degree of CRS and ACT. The outcomes of interest were two-
year recurrence rate, and sites of recurrence. 
Median with inter-quartile range (IQR 25th to 75th percentiles), mean with standard deviation, and 
counts expressed as percentages, were computed to describe the continuous and categorical 
variables respectively. Differences in variables between patients with and without recurrence within 
twenty-four months were assessed using the Pearson’s chi-square and Fisher’s exact tests. 
Association was considered statistically significant if p-value was <0.05.  
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CHAPTER FOUR: RESULTS 
4.1 Description of Baseline data 
In the hospital database, 200 patient records over a nine-year period were identified with an ovarian 
cancer diagnosis. A total of 124 EOC patients who received definitive treatment between January 
2006 and December 2014, were selected. Excluded patients were 33 (27%): 29 (88%) patients had 
platinum- resistant/refractory disease, and four (12%) patients had insufficient follow-up 
information. Of the patients with platinum-resistant or refractory disease, 22 (76%) and seven (24%) 
had advanced and early-stage disease respectively. A total of 91 patients were available for final 
analysis. Of these, 47% (43/91) and 53% (48/91) patients had early and advanced-stage disease 
respectively. In nearly 50% of patients we could not trace a record of the baseline CA125 results. 
Parity was unknown for four patents. Among stage IC patients, eight (44%) patients had FIGO IC1, 
five (28%) FIGO IC2, and five (28%) FIGO IC3 disease. Among stage IV patients, nearly 70% had stage 
IVB disease. Details of FIGO stage II and III patients are as indicted in Table 1 respectively. 
Tumour grade for endometrioid and mucinous histologies was not explicit in many reports. Twelve 
patients had combinations of mixed histology and were grouped as such for simplicity. Only two 
patients had a BRCA test performed and documented prior to 2014. The reason was that BRCA 
testing was not yet routine practice. 
Only nine percent (4/43) of patients with early-stage disease had an optimal staging operation which 
included some form of retroperitoneal lymph node assessment (only one patient had both pelvic 
and para-aortic nodal assessment), peritoneal biopsies and sampling of the hemidiaphragms. 
Peritoneal biopsy was performed randomly in 40% (15/39) of patients without diaphragmatic 
sampling. 
Most of the surgical notes did not indicate the site and size of residual tumour, but there was written 
indication whether tumour debulking was optimal or not. In cases where it was not documented, 
we analyzed the operative findings and the ease or difficulty with which the operation was done to 
determine whether cytoreduction was optimal. Some form of bowel resection (mainly 
rectosigmoid) during PDS/IDS was performed in less than 10% of the patients. No patient had 
documented peritoneal stripping or splenectomy. 
NACT was considered as at least two cycles of chemotherapy received either as single-agent or in 
combination before surgery. Of the patients with advanced disease, 39.6% (19/48) received NACT 
and 42% (8/19) of them were documented as optimally cytoreduced. Nearly 90% the patients who 
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got NACT received carboplatin and cyclophosphamide as paclitaxel was not readily available prior 
to 2014. 
ACT was not administered to 19% (17/91) of the patients due to low-risk disease. On average, six 
cycles of ACT were administered to eligible patients. Those who received 
carboplatin/cyclophosphamide, carboplatin/Taxol and single-agent carboplatin were 55%, 12% and 
11% respectively. In 15% (11/74) of the patients we could not ascertain the ACT regimen they 
received (data not shown in the tables).  
Sites of recurrence were taken as per case notes and documented imaging results which included 
mainly ultrasound and chest radiography. Computed tomography was not used often to assess 
extent of disease recurrence among patients who recurred within twelve months as they were 
considered non-surgical candidates. 
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Table 4.1: Clinical and pathologic characteristics (N=91) 
Characteristics  No. of patients (%) 
Mean-Age (years) 
(SD) 
56±12   
Median-CA125 
(IQR) 
Missing CA-125  
522.4 (86.6-1257) 47 
 
44 
51.6 
 
48.4 
Parity: 
0 
1-2 
≥3 
Missing 
  
20 
28 
39 
4 
 
22.0 
30.8 
42.8 
4.4 
    
FIGOª stage: 
IA+IB 
IC 
IIA+IIB 
IIC 
IIIA 
IIIB 
IIIC 
IV 
  
15 
20 
2 
6 
4 
5 
26 
13 
 
16.4 
22.0 
2.2 
6.6 
4.4 
5.5 
28.6 
14.3 
Histology 
Papillary Serous 
Low-grade Serous 
Clear Cell 
Endometrioid 
Mucinous 
Others* 
 
 
 
42 
9 
4 
13 
11 
12 
 
46.1 
9.9 
4.4 
14.3 
12.1 
13.2 
Cytoreductive 
surgery: 
Optimal 
Sub-optimal 
Not certain 
  
 
64 
16 
11 
 
 
70.3 
17.6 
12.1 
Surgical Staging: 
Optimal 
Sub-optimal 
  
4 
39 
 
9.3 
90.7 
NACT⁕: 
Yes 
No 
Not certain 
  
19 
28 
1 
 
39.6 
58.3 
2.1 
IDSᵇ (Stage III 
IV): 
Optimal 
Sub-optimal 
Not certain 
  
 
8 
9 
2 
 
 
42.1 
47.4 
10.5 
PDSᵈ (Stage III-IV): 
Optimal 
Sub-optimal 
Not certain 
  
 
13 
9 
6 
 
 
46.4 
32.2 
21.4 
Adjuvant 
chemotherapy: 
Yes 
No 
  
 
74 
17 
 
 
81.3 
18.7 
ª International Federation of Gynecology and Obstetrics; ᵇ Interval Debulking Surgery, ᵈ Primary Debulking Surgery; * 
Mixed and rare histologies; ⁕Neoadjuvant chemotherapy 
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4.2 Recurrence data 
The median time of follow-up was 22 months (IQR 12-58.5 months). There was high loss to follow-
up by the 24th month and vital status was difficult to ascertain. Patients who completed at least 24 
months of follow-up without documented recurrence were considered as such. Conversely, those 
who were lost to follow-up prior to 24 months were considered to have had a recurrence unless 
other cause of death was clearly documented in the hospital database. 
Among patients with disease grossly limited to the pelvis who recurred within 24 months, 14% were 
stage IA/IB, 57% stage IC, and 29% stage II. 
The combined median RFI was 12 months (IQR 8-16). Recurrence in early-stage disease occurred in 
the pelvis in half of patients. FIGO stage III/IV disease displayed a tendency towards multiple and 
distant-site recurrence.  
Table 4.2: 24-months recurrence by stage and site 
Characteristics FIGO I&II FIGO III&IV 
Recurrence, n (%)   
Yes 
No 
14 (32.6) 
29 (67.4) 
32 (66.7) 
16 (33.3) 
RFI, n (%) 
≤12 months 
13-24 months 
 
7 (50) 
7 (50) 
 
20 (62.5) 
12 (37.5) 
Median RFI* (IQR) 14 (8.75-20.75) 12 (8-14.25) 
Site of Recurrence, n (%) 
Pelvis only 
Pelvis and Abdomen 
Distant site(s) 
Site not defined** 
 
9 (60) 
3 (20) 
3 (20) 
- 
 
8 (25) 
9 (28.1) 
11 (34.4) 
4 (12.5) 
* Recurrence Free Interval in months; ⁕ Interval Debulking Surgery; ** Recurrence documented by evidence of rising CA125 
and clinical deterioration.  
4.3 Contributory factors to early recurrence 
Histology showed a strong association with two-year recurrence. Patient age, Parity, Optimal 
debulking/staging, serum CA125 and NACT did not demonstrate association. 
  
Stellenbosch University  https://scholar.sun.ac.za
22 | Page 
 
Table 4.3: Clinicopathologic factors and 24-months recurrence 
Factor Recurred ≤24months 
(N=46) 
n (%) 
No Recurrence 
(N=45) 
n (%) 
p-value 
Age (years) 
≤59 
≥60 
 
25 (54.3) 
21 (45.7) 
 
30 (66.7) 
15 (33.3) 
 
0.551 
 
Parity 
0 
1-2 
≥3 
Not certain 
 
11 (23.9) 
13 (28.3) 
20 (43.5) 
2(4.3) 
 
8 (17.8) 
15 (33.3) 
18 (40) 
4(10) 
 
0.245 
 
Baseline CA125 (U/ML) 
≤500 
≥501 
Missing 
 
7 (15.2) 
14 (30.4) 
25 (54.4) 
 
16 (35.6) 
9 (20) 
20 (44.4) 
 
0.241 
 
Histology 
Papillary Serous 
Low-grade Serous 
Clear Cell 
Endometroid 
Mucinous 
Others 
 
25 (54.4) 
7 (15.2) 
2 (4.3) 
4 (8.7) 
4 (8.7) 
4 (8.7) 
 
17 (37.8) 
2 (4.4) 
2 (4.4) 
9 (20) 
7 (15.6) 
8 (17.8) 
 
0.005 
 
NACT⁕ 
Yes 
No 
 
 
14 (30.4) 
32 (69.6) 
 
 
5 (11.1) 
40 (88.9) 
 
0.512 
 
Surgical Staging 
Optimal 
Sub-optimal 
 
3 (14.3) 
18 (85.7) 
 
1 (4.5) 
21 (95.5) 
 
0.473 
 
CRSᵉ 
Optimal 
Sub-optimal 
Not certain 
 
25 (54.4) 
14 (30.4) 
7 (15.2) 
 
39 (86.7) 
2 (4.4) 
4 (8.9) 
 
1.000 
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CHAPTER FIVE: DISCUSSION 
This retrospective single-institution study aimed to assess two-year recurrence rate, determine 
patterns of recurrence, and identify potential contributors to early recurrence. Of the 91 eligible 
women treated for EOC, 50% had disease recurrence within 24 months of completion of therapy. 
The two-year recurrence rate was 33% and 67% for early and advanced-stage disease respectively. 
The median time to recurrence was 12 months (IQR 8-16) without a statistical difference between 
the two groups. Tumour histology was the sole factor that demonstrated association with early 
recurrence with p-value=0.005. Adequacy of surgical staging or debulking, baseline serum CA125 
level, NACT, patient age, and parity did not demonstrate association. 
American and European studies have demonstrated that 25-30% of patients treated for early- stage 
disease will develop a recurrence within five years (26,40,61).  A study by Chan et al. indicated a 
median time to recurrence of 21 months among patients treated for early-stage epithelial ovarian 
cancer after a median follow up time of 5 years (20).  A 33% recurrence rate within 24 months for 
early-stage disease in our study is comparatively high. This may be attributable to under-staging of 
a significant number of patients with presumed early-stage disease. This is plausible as patients with 
early-stage disease comprised 47% of our study cohort compared to 30% in other published studies 
(62,63), as well as absence of statistical difference in RFI between early and advanced-stage disease 
patients who developed early recurrence. Available evidence indicates that about one-third of 
patients with clinical stage I/II disease in reality have stage III disease after performing pelvic and 
para-aortic lymphadenectomy (8), a procedure that was not part of routine staging surgery for our 
patients.  However, a correlation between sub-optimal surgical staging and early recurrence was 
not observed in our study. With a paltry 9% of patients undergoing optimal staging surgery, its 
impact on early recurrence cannot be excluded. It is also noteworthy that 40% of eligible patients 
had random peritoneal biopsies performed as part of staging, but none were up-staged, confirming 
an established fact that random peritoneal biopsies do not result in improved detection of 
microscopic peritoneal disease (64).  
A multi-institutional French study retrospectively evaluated 500 patients with advanced EOC, 
fallopian tube, and primary peritoneal cancer and showed that 26% (inclusive of platinum-resistant 
patients) recurred within 12 months after completion of treatment, and a further 52% recurred 
within 36 months with a median follow up of 49 months. Complete cytoreduction was achieved in 
70% of patients and  two-thirds of their cohort received NACT (65).  In the study by Gadducci and 
colleagues, 30% of all optimally cytoreduced patients with advanced-disease recurred within 12 
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months (66).  In our study, a recurrence rate of 68% within 24 months in advanced-stage-disease, 
after exclusion of platinum-resistant/refractory patients, is significantly higher than the 
aforementioned figures albeit with a 70% optimal cytoreduction rate comparable to Vidal et al. (65). 
This could be due to significant under-estimation of intra-operative residual disease volume 
resulting in a falsely high optimally-cytoreduced proportion of patients with consequent high early-
recurrence rate: an observation that augments a known fact that optimal/complete cytoreduction 
is associated with longer recurrence-free survival (51,67). Eskander and co-workers showed that 
there was poor correlation between attending surgeon’s estimate of residual tumour and post-
operative computed tomography (CT) scan findings (68). Optimal staging and documentation of size 
and site of residual disease rates for our cohort fell very short of established quality indicators (95% 
and 90% respectively) for OC surgery (69), potentially masking the expected effect of cytoreductive 
surgery on RFI. 
Our study did not demonstrate a negative effect of NACT on early recurrence. Several studies have 
shown that survival outcomes between neoadjuvant chemotherapy followed by IDS are comparable 
to PDS in patients with advanced EOC (11,46). Although patients who had NACT were more likely to 
have optimal cytoreduction, other studies indicate they were likely to recur earlier and had inferior 
survival compared to their counterparts who underwent optimal/complete PDS (66,70).  A study in 
Finland demonstrated that peri-operative visual estimation of residual disease during IDS is less 
sensitive compared to PDS potentially leading to under-estimation of residual disease (47). 
However, small numbers of patients who were given NACT in our cohort preclude a definitive 
conclusion on this subject.  
The effect of baseline serum CA125 level on early recurrence was not demonstrable. Chi et al. 
demonstrated that baseline serum CA 125 ≥ 500U/ predicted optimal cytoreduction: a factor that 
correlates with RFI, with a sensitivity of 78%, specificity of 73%, positive predictive value of 78%, 
and negative predictive value of 73% (29). Contrastingly, Memarzadeh et al. failed to confirm this 
finding albeit with higher CA 125 cut-offs (28). Our finding appears to agree with the latter’s 
observation.  
Patient age and parity did not demonstrate association with early recurrence. A Gynecologic 
Oncology Group study however, showed that patients over 60 years of age with early-stage disease 
had higher recurrence and poorer survival compared to their younger counterparts (26). Small 
patient numbers and aggregation of low and high-grade histology which are epidemiologically 
distinct entities (23) potentially masked the effect of age on early recurrence. Bodelon and 
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colleagues observed that parity had not effect on recurrence (71), an observation our finding 
reaffirms. Although pregnancy reduces the risk of EOC, it does not seem to have a bearing on tumour 
biology (72). 
Our study demonstrates the already known association between tumour histology and early 
recurrence (2,73).  However, few patients with non-serous histologies could not enable sub-group 
assessment for potential differences in recurrence rates and patterns of recurrence among early-
stage high-grade serous, clear-cell and mucinous carcinomas. Nevertheless, available evidence 
demonstrates that there is no difference in recurrence between clear cell and high-grade serous 
tumours (74). 
Regarding patterns of recurrence, isolated pelvic recurrence was diagnosed in 60% of the patients 
treated for early-stage disease. This is supported by Trimbos et al. who demonstrated similar results 
(40). Patients with advanced disease showed a logical tendency towards distant multiple site 
recurrence. Singh et al. observed similar results with a higher predisposition for multiple distant-site 
metastases among African American patients (75). We did not capture race for our cohort to 
determine if differences in recurrence patterns exist among racial groups, nevertheless our 
institution serves a predominantly black population. The minimal use of computed tomography 
imaging for patients who recurred under 12 months and its low sensitivity however potentially 
under-estimates upper abdominal and retroperitoneal recurrence in our study.  
The strengths of this study include a well-kept and legible database with access to pathologic reports 
that assured accurate histology information. Patients were managed by a multi-disciplinary team 
inclusive of trained gynaecologic oncology surgeons, medical oncologists, experienced pathologists 
and radiologists ensuring optimum management for epithelial ovarian cancer in a modest resource 
setting. 
The weaknesses of the study include the inherent bias of retrospective observational studies, 
subjective nature of retrospective evaluation of surgical notes to determine intra-operative residual 
tumour status in some cases, and inability to establish vital status of many patients due to limited 
scope of the ethics approval.  
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Conclusions 
One in three patients treated for early-stage epithelial ovarian cancer and two-thirds of those with 
advanced-stage disease recurred within 24 months with a median interval to recurrence of 12 
months. These recurrence figures are higher in comparison to Western published literature.  
The rates of optimal staging and documentation of size and site of residual tumour in our cohort fall 
very short of established quality indicators for ovarian cancer surgery. There appears to be 
significant under-estimation of intra-operative residual disease. 
Due to small patient numbers, however, we were unable to ascertain the impact of different 
chemotherapy combinations and histologic sub-types on early recurrence for this cohort. 
 
Recommendations 
A standardized protocol for ovarian cancer surgery and systematic documentation are required to 
assure adherence to established quality indicators and homogenize documentation among 
surgeons.  
An objective intra-operative method of assessment of residual disease should replace visual 
estimation to improve assessment of survival outcomes. 
An extended study to determine survival of this cohort to further inform current management 
practices is warranted. 
Disclosures. The author has no disclosures to make. The research project was not funded. 
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